We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
+18.47%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.84B
AUM Growth
+$705M
Cap. Flow
+$506M
Cap. Flow %
17.82%
Top 10 Hldgs %
58.91%
Holding
40
New
10
Increased
16
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$132M
2
RVMD icon
Revolution Medicines
RVMD
+$86.4M
3
PCVX icon
Vaxcyte
PCVX
+$85.9M
4
ARVN icon
Arvinas
ARVN
+$73.6M
5
TARS icon
Tarsus Pharmaceuticals
TARS
+$54.1M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$90.7M
2
AMAM
Ambrx Biopharma Inc
AMAM
+$62M
3
AUTL
Autolus Therapeutics
AUTL
+$38.6M
4
TGTX icon
TG Therapeutics
TGTX
+$37.1M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$314M 11.04%
4,177,830
+319,822
+8% +$25.5M
ACLX
2
DELISTED
Arcellx
ACLX
$266M 9.35%
3,818,095
+159,471
+4% +$10.1M
ARGX icon
3
argenx
ARGX
$57.4B
$217M 7.65%
552,120
+129,543
+31% +$50.2M
IRON icon
4
Disc Medicine
IRON
$2.83B
$149M 5.24%
2,389,902
+4,045
+0.2% +$262K
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$8.86B
$146M 5.15%
3,124,749
+811,830
+35% +$31.8M
SRPT icon
6
Sarepta Therapeutics
SRPT
$1.66B
$140M 4.91%
+1,078,346
New +$132M
IMCR icon
7
Immunocore
IMCR
$1.78B
$116M 4.09%
1,787,176
+333,293
+23% +$22.9M
LEGN icon
8
Legend Biotech
LEGN
$4.3B
$111M 3.91%
1,982,006
+87,362
+5% +$5.27M
ARVN icon
9
Arvinas
ARVN
$518M
$108M 3.8%
2,614,935
+1,683,632
+181% +$73.6M
XENE icon
10
Xenon Pharmaceuticals
XENE
$6.32B
$107M 3.77%
2,484,874
+357,474
+17% +$16.4M
TARS icon
11
Tarsus Pharmaceuticals
TARS
$2.56B
$104M 3.66%
2,863,406
+1,838,406
+179% +$54.1M
CERE
12
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$98.5M 3.47%
2,330,508
– –
RVMD icon
13
Revolution Medicines
RVMD
$40.2B
$93.9M 3.31%
+2,914,975
New +$86.4M
OLMA icon
14
Olema Pharmaceuticals
OLMA
$1.02B
$89.5M 3.15%
7,903,600
– –
VRDN icon
15
Viridian Therapeutics
VRDN
$2.13B
$88.1M 3.1%
5,031,420
+236,932
+5% +$4.59M
PCVX icon
16
Vaxcyte
PCVX
$7.89B
$84.7M 2.98%
+1,239,995
New +$85.9M
ALPN
17
DELISTED
Alpine Immune Sciences Inc
ALPN
$84.1M 2.96%
2,121,163
-1,055,580
-33% -$31.1M
BCYC
18
Bicycle Therapeutics
BCYC
$270M
$80.8M 2.85%
3,246,759
-460,242
-12% -$9.78M
ASND icon
19
Ascendis Pharma A/S
ASND
$16.7B
$76.8M 2.7%
507,952
+156,252
+44% +$22.3M
KURA icon
20
Kura Oncology
KURA
$922M
$66.9M 2.35%
3,135,387
+1,872,559
+148% +$36.4M
EWTX icon
21
Edgewise Therapeutics
EWTX
$4.39B
$44.6M 1.57%
+2,446,373
New +$38.9M
AUTL
22
Autolus Therapeutics
AUTL
$386M
$41M 1.44%
6,425,803
-6,185,532
-49% -$38.6M
YMAB
23
DELISTED
Y-mAbs Therapeutics
YMAB
$36.3M 1.28%
+2,233,610
New +$30.1M
IMTX icon
24
Immatics
IMTX
$1.24B
$29.6M 1.04%
2,818,908
+682,569
+32% +$7.96M
IMVT icon
25
Immunovant
IMVT
$8.09B
$25.8M 0.91%
+799,054
New +$29.2M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $4.87B AUM 25.35% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MSRPS
Maryland State Retirement & Pension System Baltimore, Maryland $4.92B AUM 28.48% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return

Paradigm Biocapital Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Paradigm Biocapital Advisors held 40 positions worth $2.84B, up 33% from $2.14B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Paradigm Biocapital Advisors deployed $506M of net new capital in Q1 2024, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was Sarepta Therapeutics: 1,078,346 shares worth $140M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Autolus Therapeutics, an estimated $38.6M trimmed.

  • Paradigm Biocapital Advisors's largest Q1 2024 buy was Sarepta Therapeutics: 1,078,346 shares worth $140M.
  • Paradigm Biocapital Advisors added most to Arvinas in Q1 2024, an estimated $73.6M increase.
  • Paradigm Biocapital Advisors's biggest Q1 2024 reduction was Autolus Therapeutics, cutting an estimated $38.6M.
  • Paradigm Biocapital Advisors fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $90.7M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 59% of its $2.84B portfolio in Q1 2024.
  • Paradigm Biocapital Advisors opened 10 new positions and closed 6 in Q1 2024.
  • Paradigm Biocapital Advisors's portfolio value rose 33% quarter-over-quarter to $2.84B.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2024, filed 15 May 2024.